Oct
2026
Fiera Milano, Italy
Visit us
stand 14F42, Finished Dosage & Formulation
Huayi Pharmaceutical (Anhui) co. ltd
Exhibitor at CPHI Milan 2026
About Us
Categories
-
Country/Region:China
-
On CPHI since:2021
-
Certificates:2
-
Employees:250 - 499
Company types
Event information
CPHI Milan 2026
-
6 Oct 2026 - 8 Oct 2026
-
Fiera Milano, Italy
-
Visit us at stand 14F42, Finished Dosage & Formulation
Products Featured at CPHI Milan 2026
-
Product Commercial production
Various manufacturing processes available and flexible batch sizes.
Each process is equipped with multiple production function rooms,and each function room adopts an independent HVAC system to minimizecross-contamination during manufacturing of multiple products.
Capacity: 13 billion tablet... -
Product Pharmaceutical Development
Meet customers’ diversified demands for R&D
Provide customers with comprehensive support from R&D to manufacturing, covering multiple dosage form development, including solid preparation (tablets, capsules, granules), liquid preparations (oral solutions, injections), and semi-solid preparati... -
Product Licensing out
Licensing out after successful development. -
Product Out-licensing
Seeking sales partners for our European licensed products, focusing on providing customers with out-licensing and commercial manufacturing services and testing and release services for the European market according to customers’ requirements. Several products approved and several products under application... -
Product API cooperation
1. API customization service
Provide high-efficient API customization and process optimization services for customers as complementary service to preparation development to effectively breaking the monopoly on API supply, preventing market monopolization and controlling costs.
2. Indian API ag...
Huayi Pharmaceuticals (Anhui) Co.,Ltd Resources (1)
-
Video Huayi Pharmaceuticals
Huayi Pharmaceutical (Anhui) Co. Ltd. is an EU cGMP approved Sino-British joint venture located in Hefei, Eastern China. We manufacture quality generic medicines on a contractual basis for EU and Chinese customers with competitive pricing.




